---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-029221"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-04T23:55:24.733865+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Olema reports FY2023 net loss $96.7M, cash $261.8M; palazestrant Phase 3 underway

## Summary
- Cash, equivalents and marketable securities $261.8M as of Dec 31, 2023; net loss $96.7M for FY2023 vs $104.8M in FY2022.
- GAAP R&D expenses $86.1M in FY2023 (including $11.8M stock-based comp); non-GAAP R&D $74.4M.
- Pivotal Phase 3 OPERA-01 monotherapy trial initiated Q4 2023; top-line results expected in 2026.
- Phase 2 study of palazestrant + ribociclib (60 patients) fully enrolled; data at ESMO Breast Cancer May 2024.
- KAT6 inhibitor OP-3136 nominated as development candidate; IND filing expected late 2024.

## SEC filing metadata
- accession: 0000950170-24-029221
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000095017024029221/0000950170-24-029221-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000095017024029221/olma-20240311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-029221
- JSON: https://secwatch.observer/filing/0000950170-24-029221.json
- Plain text: https://secwatch.observer/filing/0000950170-24-029221.txt

## Key facts
- Earnings Releases
  Olema Pharmaceuticals, Inc. reported the fourth quarter ended December 31, 2023 results: net income Net loss was $26.8 million.
  - Period: the fourth quarter ended December 31, 2023
  - Net income: Net loss was $26.8 million
  - Result: reported results
  source text: Net loss was $26.8 million and $96.7 million for the quarter and year ended December 31, 2023, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750284/000095017024029221/0000950170-24-029221-index.htm
- Earnings Releases
  Olema Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2023 results: net income Net loss was $96.7 million.
  - Period: the fiscal year ended December 31, 2023
  - Net income: Net loss was $96.7 million
  - Result: reported results
  source text: Net loss was $26.8 million and $96.7 million for the quarter and year ended December 31, 2023, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750284/000095017024029221/0000950170-24-029221-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.